Bioactivity | Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous angiotensin type 2 receptor (AT2R) agonist, with IC50s of 0.648 nM and 21.1 nM for AT2R and AT1R, respectively. | ||||||
Target | IC50: 0.648 nM (AT2R), 21.1 nM (AT1R) | ||||||
Invitro | Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous angiotensin type 2 receptor (AT2R) agonist, with IC50s of 0.648 nM and 21.1 nM for AT2R and AT1R, respectively[1]. | ||||||
In Vivo | Angiotensin III (7, 14 and 28 nmol/kg/min) increases urine sodium excretion (UNaV), fractional excretion of sodium (FENa), and fractional excretion of lithium (FELi) in SD rat[2]. In RAS (renin-angiotensin system), Angiotensin III increases sympathetic nerve activity and vasopressin release and decreases the baroreflex leading to higher blood pressure in rats[3]. | ||||||
Name | Angiotensin III, human, mouse | ||||||
CAS | 13602-53-4 | ||||||
Sequence | Arg-Val-Tyr-Ile-His-Pro-Phe | ||||||
Shortening | RVYIHPF | ||||||
Formula | C46H66N12O9 | ||||||
Molar Mass | 931.09 | ||||||
Appearance | Solid | ||||||
Transport | Room temperature in continental US; may vary elsewhere. | ||||||
Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||
Reference | [1]. Bosnyak S, et al. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond). 2011 Oct;121(7):297-303. [2]. Kemp BA, et al. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension. 2012 Aug;60(2):387-95. [3]. Gao J, et al. A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors. Clin Sci (Lond). 2014 Aug;127(3):135-48. |